Evercore ISI Group analyst James West maintains Noble Corp (NYSE:NE) with a Outperform and raises the price target from $49 to $53.
NexImmune Q2 EPS $(0.69) Down From $(0.54) YoY
NexImmune (NASDAQ:NEXI) reported quarterly losses of $(0.69) per share. This is a 27.78 percent decrease over losses of $(0.54) per share from the same period last year.